Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Bad financial results growth rate -2.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.6%)
  • Dividend yield for the last twelve months 5.2%
  • Free cash flow yield 7.5% (LTM)
  • Share price is 19.4% higher than minimum and 41.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (22.7x vs
    )

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+1.0%)47.34
year average price 52.75  


year start price 41.20 2024-07-16

min close price 41.20 2024-07-16

max close price 63.11 2025-03-10

current price 47.34 2025-07-15
Common stocks: 2 111 517 922

Dividend Yield:  5.2%
FCF Yield LTM: 7.5%
EV / LTM EBITDA: 22.7x
EV / EBITDA annualized: 11.7x
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 99 959
Net Debt ($m): 38 895
EV (Enterprise Value): 138 854
EBITDA LTM ($m): 6 108
EV / LTM EBITDA: 22.7x
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-14benzinga.com

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

2025-07-14247wallst.com

$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run

2025-07-10seekingalpha.com

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

2025-07-10seekingalpha.com

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

2025-07-08cnbc.com

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

2025-07-07seekingalpha.com

2 Wonderful Dividends At Bargain Basement Prices

2025-07-07247wallst.com

Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income

2025-07-03zacks.com

Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

2025-06-30zacks.com

BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

2025-06-29seekingalpha.com

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data